Get a free sample of Lenalidomide Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Lenalidomide Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Lenalidomide Market Size
Lenalidomide Market size was valued at USD 18 billion in 2023 and is anticipated to register a CAGR of 5.1% between 2024 and 2032. This surge is propelled by various factors, including the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavours.
Furthermore, the demand for lenalidomide remains vigorous, buoyed by its proven efficacy in managing multiple myeloma. A report from the American Association for Cancer Research and the National Cancer Institute's Epidemiology and End Results (SEER) program highlights that in 2022, 34,470 individuals in the U.S. were diagnosed with multiple myeloma, underscoring the increasing need for efficacious treatment options.
Lenalidomide is a medication classified as an immunomodulatory agent. It is primarily used in the treatment of certain types of cancer, particularly multiple myeloma, and myelodysplastic syndromes. Lenalidomide works by affecting the immune system and helping to slow down the growth of cancer cells.
Why is the demand for 10mg lenalidomide capsules increasing?
The 10mg capsules segment generated USD 6.1 billion in revenue in 2023 and is projected to record substantial growth through 2032 as these capsules serve as a cornerstone in medical treatment regimens for offering patients a reliable and standardized dosage.
What is the size of the lenalidomide market?
Lenalidomide industry size was worth USD 18 billion in 2023 and is set to expand at 5.1% CAGR from 2024-2032 propelled by the escalating prevalence of multiple myeloma worldwide and continuous advancements spurred by research endeavors.
How big is the North America lenalidomide industry?
North America lenalidomide market accounted for a sizeable revenue share in 2023 and is expected to expand at a significant growth rate through 2032 owing to the heightened incidence rate of these diseases in comparison to other regions globally.
Who are the leading lenalidomide industry players?
Some of the major lenalidomide firms are Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Viatris Inc., among others.